OM Stock Recent News

SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of healthcare industry veteran Kevin O'Boyle to its Board of Directors and as chair of its Audit Committee. With Mr. O'Boyle's appointment, the company also announced that Dale E. Jones has stepped down from the Board.

SAN JOSE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate at the RBC Capital Markets Global Health Care conference on Tuesday, May 20, 2025, at 10:30 a.m. Eastern time.

Outset Medical, Inc. (OM) Q1 2025 Earnings Call Transcript

Outset Medical, Inc. (OM) came out with a quarterly loss of $3.24 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to loss of $8.55 per share a year ago.

SAN JOSE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended March 31, 2025.

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Outset Medical, Inc. (NASDAQ:OM) on behalf of long-term stockholders following a class action complaint that was filed against Outset Medical on August 29, 2024 with a Class Period from August 1, 2022 to August 7, 2024. Our investigation concerns whether the board of directors of Outset Medical have breached their fiduciary duties to the company.

The consensus price target hints at a 71.7% upside potential for Outset Medical (OM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

The consensus price target hints at an 188.6% upside potential for Outset Medical (OM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

SAN JOSE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced a one-for-fifteen reverse stock split (the “Reverse Stock Split”) of the Company's common stock, par value $0.001, which will become effective at 12:01 a.m. Eastern Time on Thursday, March 20, 2025. The Company's common stock will continue to trade under Outset's existing trading symbol, OM, on the Nasdaq Global Select Market (“Nasdaq”) on a split-adjusted basis when the market opens on Thursday, March 20, 2025, with the new CUSIP number 690145206.

Outset Medical (OM) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.